Kancera Past Earnings Performance

Past criteria checks 0/6

Kancera's earnings have been declining at an average annual rate of -11.2%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been declining at an average rate of 96.1% per year.

Key information

-11.2%

Earnings growth rate

23.1%

EPS growth rate

Biotechs Industry Growth0.7%
Revenue growth rate-96.1%
Return on equity-63.9%
Net Marginn/a
Next Earnings Update15 Nov 2024

Recent past performance updates

Recent updates

Companies Like Kancera (STO:KAN) Are In A Position To Invest In Growth

Aug 13
Companies Like Kancera (STO:KAN) Are In A Position To Invest In Growth

We Think Kancera (STO:KAN) Needs To Drive Business Growth Carefully

Dec 06
We Think Kancera (STO:KAN) Needs To Drive Business Growth Carefully

Is Kancera (STO:KAN) In A Good Position To Deliver On Growth Plans?

Jul 19
Is Kancera (STO:KAN) In A Good Position To Deliver On Growth Plans?

Companies Like Kancera (STO:KAN) Are In A Position To Invest In Growth

Mar 08
Companies Like Kancera (STO:KAN) Are In A Position To Invest In Growth

We Think Kancera (STO:KAN) Can Afford To Drive Business Growth

Jun 29
We Think Kancera (STO:KAN) Can Afford To Drive Business Growth

We're Hopeful That Kancera (STO:KAN) Will Use Its Cash Wisely

Mar 08
We're Hopeful That Kancera (STO:KAN) Will Use Its Cash Wisely

Here's Why We're Watching Kancera's (STO:KAN) Cash Burn Situation

Aug 02
Here's Why We're Watching Kancera's (STO:KAN) Cash Burn Situation

We're Not Very Worried About Kancera's (STO:KAN) Cash Burn Rate

Apr 06
We're Not Very Worried About Kancera's (STO:KAN) Cash Burn Rate

Here's Why We're Not Too Worried About Kancera's (STO:KAN) Cash Burn Situation

Dec 21
Here's Why We're Not Too Worried About Kancera's (STO:KAN) Cash Burn Situation

Revenue & Expenses Breakdown

How Kancera makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

OM:KAN Revenue, expenses and earnings (SEK Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 240-53748
31 Mar 240-60854
31 Dec 230-65858
30 Sep 230-60853
30 Jun 230-61952
31 Mar 230-58850
31 Dec 220-52746
30 Sep 220-51647
30 Jun 220-52449
31 Mar 220-49545
31 Dec 210-46443
30 Sep 210-45641
30 Jun 210-44639
31 Mar 210-38538
31 Dec 200-40639
30 Sep 200-35435
30 Jun 200-34434
31 Mar 200-40834
31 Dec 193-36735
30 Sep 194-41841
30 Jun 193-44845
31 Mar 193-41644
31 Dec 180-46545
30 Sep 180-46447
30 Jun 180-52551
31 Mar 180-59559
31 Dec 170-56556
30 Sep 170-51546
30 Jun 170-39436
31 Mar 170-27423
31 Dec 160-22319
30 Sep 160-22522
30 Jun 160-20520
31 Mar 160-20520
31 Dec 150-20520
30 Sep 150-19316
30 Jun 150-18316
31 Mar 150-17314
31 Dec 140-16314
30 Sep 142-13312
30 Jun 142-13311
31 Mar 142-12410
31 Dec 132-748

Quality Earnings: KAN is currently unprofitable.

Growing Profit Margin: KAN is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: KAN is unprofitable, and losses have increased over the past 5 years at a rate of 11.2% per year.

Accelerating Growth: Unable to compare KAN's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: KAN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-20.8%).


Return on Equity

High ROE: KAN has a negative Return on Equity (-63.93%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies